Form 4: Insmed CFO Sara Bonstein Executes Stock Sale

Insmed Chief Financial Officer Sara Bonstein sold 8,272 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• CFO Sara Bonstein sold 8,272 shares of Insmed Inc (INSM) common stock.
• The transaction occurred on May 13, 2026, at a price of $116.18 per share.
• Following the sale, the reporting person retains beneficial ownership of 71,486 shares.
• The sale was executed to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely for tax compliance and does not reflect a change in the executive's outlook on the company.

Positives

• The transaction was a routine administrative action to cover tax liabilities rather than a discretionary divestment.

Negatives

• Reduction in the direct equity stake held by the Chief Financial Officer.

Risks

• None identified; this is a standard tax-related transaction.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes are common in the biotechnology sector, where equity-based compensation is a significant component of executive remuneration packages.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive tax obligations.
• The sale does not indicate a change in management sentiment regarding the company's long-term prospects.

Stakeholder Impact

• Minimal impact on shareholders as the sale was non-discretionary.

Key Dates

Keywords

Insmed, INSM, Insider Trading, Form 4, CFO, Equity Compensation